Care Access - a global research company helping accelerate the arrival of new medicines - is working with seniors at its Lake Charles, La., location on a research study for an investigational treatment which aims to slow or prevent the onset of Alzheimer’s disease symptoms. Alzheimer’s disease impacts one out of nine adults over the age of 65 in the U.S. The TRAILBLAZER-ALZ 3 study, by Eli Lilly and Company, utilizes a new experimental blood test that can detect a biomarker known to identify the early preclinical phase of Alzheimer’s, which can start 10 to 20 years before symptoms appear.
As a result of this blood test, potentially at-risk participants can check for early pre-symptomatic signs of Alzheimer’s. Those who have elevated blood test results may be eligible for the opportunity to participate in the study of an investigative medicine, donanemab, to evaluate if it significantly slows down or stops the onset of memory loss and other debilitating Alzheimer’s symptoms.
“Alzheimer’s is a devastating form of dementia that afflicts over 6 million Americans,” said Dr. Jason Morris, MD, the Care Access Principal Investigator for this study in Lake Charles. “Detecting early preclinical Alzheimer’s, which can start 10 to 20 years before you have symptoms, with a simple blood test is an important opportunity for seniors here in our Lake Charles community. If the blood test result is elevated, there’s an exciting prevention study you may be able to take part in.”
The Phase 3 study is currently looking for healthy adults ages 65-80 who do not have signs of cognitive impairment, memory loss, or dementia. If you or someone you know is interested or wants to participate in this study, visit TestforALZ.com, or contact Care Access at 337-223-9696 to learn more.
Care Access opened its Lake Charles location in 2020, in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the greater Lake Charles community.
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by biopharmaceutical companies of all sizes, including 14 of the top 20 biopharma. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality clinical trial infrastructure locally to achieve the common goal of improving health outcomes for generations to come. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach and (3) staffing support and training services for all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814055594/en/
Copyright Business Wire 2023